JP2002528502A5 - - Google Patents

Download PDF

Info

Publication number
JP2002528502A5
JP2002528502A5 JP2000579225A JP2000579225A JP2002528502A5 JP 2002528502 A5 JP2002528502 A5 JP 2002528502A5 JP 2000579225 A JP2000579225 A JP 2000579225A JP 2000579225 A JP2000579225 A JP 2000579225A JP 2002528502 A5 JP2002528502 A5 JP 2002528502A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
hydrate
tipranavir
ritonavir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000579225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002528502A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/021469 external-priority patent/WO2000025784A1/en
Publication of JP2002528502A publication Critical patent/JP2002528502A/ja
Publication of JP2002528502A5 publication Critical patent/JP2002528502A5/ja
Pending legal-status Critical Current

Links

JP2000579225A 1998-11-04 1999-10-29 チプラナビルの薬物動態を改善する方法 Pending JP2002528502A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10696398P 1998-11-04 1998-11-04
US60/106,963 1998-11-04
PCT/US1999/021469 WO2000025784A1 (en) 1998-11-04 1999-10-29 Method for improving the pharmacokinetics of tipranavir

Publications (2)

Publication Number Publication Date
JP2002528502A JP2002528502A (ja) 2002-09-03
JP2002528502A5 true JP2002528502A5 (enExample) 2006-06-22

Family

ID=22314155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000579225A Pending JP2002528502A (ja) 1998-11-04 1999-10-29 チプラナビルの薬物動態を改善する方法

Country Status (13)

Country Link
US (1) US6147095A (enExample)
EP (1) EP1126847A1 (enExample)
JP (1) JP2002528502A (enExample)
CN (1) CN1154491C (enExample)
AU (1) AU762349B2 (enExample)
BR (1) BR9914940A (enExample)
CA (1) CA2346131C (enExample)
CO (1) CO5160321A1 (enExample)
HK (1) HK1040625B (enExample)
MY (1) MY118526A (enExample)
PE (1) PE20001296A1 (enExample)
TW (1) TW580387B (enExample)
WO (1) WO2000025784A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
UA78689C2 (en) * 2000-10-31 2007-04-25 Boehringer Ingelheim Pharma Pyranone-based pharmaceutical composition (variants)
DE10108470A1 (de) * 2001-02-22 2002-09-05 Boehringer Ingelheim Pharma Verfahren zur Herstellung optisch aktiver Dihydropyrone
US6500963B2 (en) 2001-02-22 2002-12-31 Boehringer Ingelheim Pharma Kg Process for preparing optically active dihydropyrones
US20040197321A1 (en) * 2002-03-19 2004-10-07 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20030180279A1 (en) * 2002-03-19 2003-09-25 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
KR20050085681A (ko) * 2002-12-16 2005-08-29 베링거 인겔하임 인터내셔날 게엠베하 프로테아제 억제제와 같은 사이토크롬 ｐ450의 억제제와함께 비-뉴클레오시드 역전사효소 억제제(ｎｎｒｔｉ)를함유하는 배합물의 용도
CA2509731A1 (en) * 2002-12-16 2004-07-22 Boehringer Ingelheim Pharmaceuticals, Inc. Treatment of hiv infection through combined administration of tipranavir and capravirine
EP1610781A1 (en) * 2003-03-27 2006-01-04 Boehringer Ingelheim International GmbH Antiviral combination of tipranavir and a further antiretroviral compound
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
JP2008519073A (ja) * 2004-11-08 2008-06-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びエトラビリンの同時投与によるｈｉｖ感染症の治療法
EP1814547A1 (en) * 2004-11-16 2007-08-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and darunavir
WO2006055660A2 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
JP2008520701A (ja) * 2004-11-19 2008-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びレバーセットの同時投与を介したｈｉｖ感染症の治療方法
WO2006060159A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw695634
WO2006060177A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw873140
EP1819335A1 (en) * 2004-12-01 2007-08-22 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and sch-417690
WO2008112289A2 (en) 2007-03-12 2008-09-18 Nektar Therapeutics Oligomer-protease inhibitor conjugates
WO2009114151A1 (en) * 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
US20100021505A1 (en) * 2008-07-28 2010-01-28 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
JP2012530069A (ja) 2009-06-12 2012-11-29 ネクター セラピューティックス プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体
US20130023496A1 (en) * 2010-04-02 2013-01-24 Randy Tressler Combination Therapy Comprising A CCR5 Antagonist, A HIV-1 Protease Inhibtior and a Pharmacokinetic Enhancer
AU2012262322B2 (en) * 2011-05-30 2016-11-03 Autotelic Llc Methods and compositions for therapeutic drug monitoring and dosing by point-of-care pharmacokinetic profiling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608085A (en) * 1995-02-27 1997-03-04 The University Of Tennessee Research Corporation Synthesis of optically active calanolides A and B and enantiomers and related compounds
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5932570A (en) * 1996-11-08 1999-08-03 Dupont Pharmaceuticals Company 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Similar Documents

Publication Publication Date Title
JP2002528502A5 (enExample)
RU2329050C2 (ru) Комбинация ингибиторов цитохром-р450-зависимых протеаз
JP2004509061A5 (enExample)
BG106906A (bg) Пуринови производни
CA2401569A1 (en) Low dose entecavir formulation and use
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
CA2302700A1 (en) New use for budesonide and formoterol
JP2005515966A5 (enExample)
JP2001510795A5 (enExample)
CA2513567A1 (en) Cop 1 for treatment of inflammatory bowel diseases
CA2503810A1 (en) Therapeutic agent for fibromyalgia
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
JP2004537500A5 (enExample)
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
JP2005508963A5 (enExample)
JP2002523437A5 (enExample)
JP2003514025A5 (enExample)
CA2313270A1 (en) Use of deferiprone in treating and preventing iron-induced cardiac disease
JP2012525358A5 (enExample)
JP2002530353A5 (enExample)
JP2002540148A5 (enExample)
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
JP2003503453A5 (ja) ガバペンチンおよびプレガバリンを含む相乗作用組成物
ATE192926T1 (de) Flavopereirine enthaltende zusammensetzung und ihre anwendung in der behandlung gegen hiv-viren
CA2474703A1 (en) Therapeutic agent of glaucoma comprising bunazosin and prostaglandins